ImpriMed, Inc., a Palo Alto, Calif.-based veterinary precision medicine startup, closed a total of $8m in Pre-Series A funding with $7.7m from VCs and the rest as government grant.
The round was led by HG Initiative and other participants include Draper Associates, Draper Dragon, BonAngels, Murex Partners, Translink Investment, Primer Sazze, FuturePlay, and ES Investor.
The company plans to use the new funding to develop additional prediction models for their current target patients in canine blood cancers, scale up their customer network, and expand pipelines to other types of cancers in dogs and cats.
Led by Dr. Sungwon Lim, CEO and Co-Founder, ImpriMed utilizes artificial intelligence (AI) to predict which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia using live data generated from chemosensitivity and immunophenotyping assays on the patient’s fresh cancer cells. Its innovative approach to pet cancer care enables veterinary oncologists to make chemotherapy decisions with confidence, knowing quantified drug response predictions prior to actual drug administration.
So far, more than 2,000 services have been provided to community treated canine patients.